Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2024-N-2219]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of four new drug applications (NDAs) from multiple holders of those NDAs. The basis for the withdrawal is that these NDA holders have repeatedly failed to file required annual reports for the identified NDAs.
 DATES: Approval is withdrawn as of September 23, 2024.
 FOR FURTHER INFORMATION CONTACT: Kimberly Lehrfeld, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6226, Silver Spring, MD 20993-0002, 301-796-3137, 
                        *Kimberly.Lehrfeld@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION: The holder of an approved application to market a new drug for human use is required to submit annual reports to FDA concerning its approved application in accordance with § 314.81 (21 CFR 314.81). In the 
                    **Federal Register**
                     of May 28, 2024 (89 FR 46139), FDA published a notice offering an opportunity for a hearing (NOOH) on a proposal to withdraw approval of four NDAs because the holders of those NDAs had repeatedly failed to submit the required annual reports for those NDAs. The holders of those NDAs did not respond to the NOOH. Failure to file a written notice of participation and request for hearing as required by § 314.200 (21 CFR 314.200) constitutes an election by those holders of the NDAs not to make use of the opportunity for a hearing concerning the proposal to withdraw approval of their NDAs and a waiver of any contentions concerning the legal status of the drug products. Therefore, FDA is withdrawing approval of the four applications listed in table 1 of this document. Table 1—Approved NDAs for Which Required Reports Have Not Been Submitted
Application No.
Drug
HolderNDA 004652
ORETON (testosterone) Pellets for Subcutaneous Implantations, 75 milligrams (mg)
Progynon Associates, 9300 Wilshire Blvd., Beverly Hills, CA 90212.NDA 013268
WINSTEROID (stanozolol) Tablets, 2 mg
Sterling Winthrop Inc., 90 Park Ave., New York, NY 10016.NDA 017455
Copper T Model TCu 200B (copper) Intrauterine Device
Duramed Research, Inc., 425 Privet Rd., Horsham, PA 19044.NDA 205003
PRESTALIA (amlodipine besylate/perindopril arginine) Tablets, equivalent to (EQ) 2.5 mg base/3.5mg, EQ 5 mg base/7 mg, and EQ 10 mg base/14 mg
Adhera Therapeutics, Inc., 224 Holding Ave., Wake Forest, NC 27588.
 FDA finds that the holders of the NDAs listed in table 1 have repeatedly failed to submit reports required by § 314.81. In addition, under § 314.200, FDA finds that the holders of the NDAs have waived any contentions concerning the legal status of the drug products. Therefore, under these findings, approval of the NDAs listed in table 1 and all amendments and supplements thereto are hereby withdrawn as of September 23, 2024. Dated: September 16, 2024. Lauren K. Roth, Associate Commissioner for Policy.


[FR Doc. 2024-21680 Filed 9-20-24; 8:45 am] BILLING CODE 4164-01-P